by mratner

BY BRUCE GOLDMAN

Lawrence Steinman

A clinical trial of a vaccine, led by Stanford University School of Medicine researchers and designed to combat type-1 diabetes, has delivered initially promising results, suggesting that it may selectively counter the errant immune response that causes the disease.